Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2014

View Archived Issues

Novel genetic variants associated with susceptibility to anorexia nervosa

Novel biological candidate SM-101 shows promise in phase II trials in patient with SLE

FDA grants imiquimod orphan status for carcinoma in situ of the urinary bladder

Liposome encapsulated paclitaxel receives U.S. orphan designation for gastric cancer

Neurocrine Biosciences begins phase I/II trial of NBI-77860

Nihon Medi-Physics patents Abeta imaging agents

International PANACEA study opens in patients with HER2+ breast cancer

Phase II data for sotatercept as treatment of anemia in hemodialysis subjects

PF-06747143: a novel CXCR4 antagonist antibody for the treatment of hematological malignancies

Clinical studies of lucitanib in breast cancer

Karyopharm begins third registration-directed trial of selinexor

Taiho Pharmaceutical divulges PKB inhibitors

Oral Health Australia reports propeptides for periodontal diseases

Novel vinca alkaloids presented by Gedeon Richter

Noribogaine HCl safe and well tolerated in healthy volunteers

Plexxikon and QuantumLeap select PLX-3397 for I-SPY 2 TRIAL in breast cancer

FDA accepts IND application for AGT-182 for the treatment of Hunter syndrome

Pieris begins phase I study of Anticalin to treat anemia

NIHR confirms start of study to test new drug for Sjogren's syndrome

CardioKinetix signs agreement with Edwards Lifesciences

FDA grants conditional approval to Cytori Cell Therapy for trial in scleroderma

FDA approves Quidel's AmpliVue Bordetella Assay

Navidea establishes Macrophage Therapeutics to develop drugs targeting activated macrophages

Lakewood-Amedex submits IND application for phase I/II trial of Nu-3 in diabetic foot ulcer

FDA approves MP Biomedicals' test to confirm HTLV-I/II antibodies

Geneva team pauses VSV-ZEBOV vaccinations following cases of joint pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...